AU2003259358A1 - Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use - Google Patents

Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use

Info

Publication number
AU2003259358A1
AU2003259358A1 AU2003259358A AU2003259358A AU2003259358A1 AU 2003259358 A1 AU2003259358 A1 AU 2003259358A1 AU 2003259358 A AU2003259358 A AU 2003259358A AU 2003259358 A AU2003259358 A AU 2003259358A AU 2003259358 A1 AU2003259358 A1 AU 2003259358A1
Authority
AU
Australia
Prior art keywords
immunogenic composition
therapeutic use
cell epitopes
epitopes
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003259358A
Other languages
English (en)
Other versions
AU2003259358A8 (en
Inventor
Claire Ashman
Jonathan Henry Ellis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0220212A external-priority patent/GB0220212D0/en
Priority claimed from GB0304672A external-priority patent/GB0304672D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2003259358A8 publication Critical patent/AU2003259358A8/xx
Publication of AU2003259358A1 publication Critical patent/AU2003259358A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003259358A 2002-08-30 2003-08-28 Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use Abandoned AU2003259358A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0220212.5 2002-08-30
GB0220212A GB0220212D0 (en) 2002-08-30 2002-08-30 Vaccine
GB0304672.9 2003-02-28
GB0304672A GB0304672D0 (en) 2003-02-28 2003-02-28 Vaccines
PCT/GB2003/003703 WO2004019974A2 (en) 2002-08-30 2003-08-28 Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use

Publications (2)

Publication Number Publication Date
AU2003259358A8 AU2003259358A8 (en) 2004-03-19
AU2003259358A1 true AU2003259358A1 (en) 2004-03-19

Family

ID=31980003

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003259358A Abandoned AU2003259358A1 (en) 2002-08-30 2003-08-28 Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use

Country Status (8)

Country Link
US (1) US20060147417A1 (https=)
EP (1) EP1532172A2 (https=)
JP (1) JP2006503017A (https=)
AR (1) AR041086A1 (https=)
AU (1) AU2003259358A1 (https=)
CA (1) CA2496409A1 (https=)
TW (1) TW200407162A (https=)
WO (1) WO2004019974A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004019975A2 (en) * 2002-08-30 2004-03-11 Glaxo Group Limited Il-14 vaccine for the treatment of asthma and atopic disorders
PL3718564T3 (pl) 2003-12-23 2024-03-18 Genentech, Inc. Nowe przeciwciała anty-IL 13 i ich zastosowania
DE102004003572A1 (de) * 2004-01-23 2005-08-18 Bavarian Nordic A/S Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
KR100639397B1 (ko) * 2004-03-18 2006-10-26 (주)에스제이바이오메드 항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물
EP1824886B1 (en) 2004-11-17 2010-12-22 Amgen Inc. Fully human monoclonal antibodies to il-13
GB0615881D0 (en) * 2006-08-10 2006-09-20 Univ Southampton Novel peptide for treatment of asthma
MX2009003188A (es) * 2006-09-25 2009-05-22 Sj Biomedic Inc Polipeptidos hibridos inmunogenicos antiobesidad y composicion de vacuna antiobesidad que comprende los mismos.
WO2011003138A1 (en) * 2009-07-06 2011-01-13 The Australian National University Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor
WO2015017034A1 (en) * 2013-08-02 2015-02-05 Gourdie Robert G Methods of treating a cancer through targeted disruption of alpha connexin 43-zonula occludens-1 (zo-1) interaction
CN120904322A (zh) 2013-09-13 2025-11-07 豪夫迈·罗氏有限公司 包含纯化的重组多肽的方法和组合物
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
WO2019061297A1 (zh) * 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 一种cd4辅助性t细胞表位融合肽及其疫苗
EP3574915A1 (en) 2018-05-29 2019-12-04 Neovacs Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
JP7569091B2 (ja) 2018-12-28 2024-10-17 ユナイテッド・バイオメディカル・インコーポレーテッド インターロイキン６（ｉｌ－６）調節異常による影響を受ける疾患の免疫療法のための、ｉｌ－６を標的とするペプチド免疫原及びその製剤
JP2024504194A (ja) * 2021-01-29 2024-01-30 エランコ アニマル ヘルス ゲー・エム・ベー・ハー 自己寛容を破壊するためのワクチン組成物
CA3229324A1 (en) * 2021-08-20 2023-02-23 Beatrice DROUET Mrna vaccines comprising il-4 and/or il-13 rna and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
US6296843B1 (en) * 1998-04-03 2001-10-02 The Penn State Research Foundation Mutagenized IL 13-based chimeric molecules
HUP0200958A3 (en) * 1999-04-23 2004-11-29 Pharmexa As Method for down-regulating il5 activity
EP1263785A2 (en) * 1999-11-11 2002-12-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Mutated il-13 molecules and their uses
US6846486B1 (en) * 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens

Also Published As

Publication number Publication date
AU2003259358A8 (en) 2004-03-19
CA2496409A1 (en) 2004-03-11
AR041086A1 (es) 2005-04-27
TW200407162A (en) 2004-05-16
US20060147417A1 (en) 2006-07-06
WO2004019974A2 (en) 2004-03-11
JP2006503017A (ja) 2006-01-26
WO2004019974A3 (en) 2004-07-22
EP1532172A2 (en) 2005-05-25

Similar Documents

Publication Publication Date Title
SI1513873T1 (sl) Terapevtski epitopi in njihova uporaba
AU2003259358A1 (en) Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
IL201916A (en) Stem cells from human placenta, their characteristics, preparation and use
AU2003221683A1 (en) Thermal interface materials and methods for their preparation and use
AU2003248721A1 (en) Adsorbents, methods of preparation, and methods of use thereof
AU2003243984A1 (en) Hydrogenated copolymer and composition thereof
AU2003237788A1 (en) Electrode constructs, and related cells and methods
AU2003239614A1 (en) Cardiolipin compositions, methods of preparation and use
AU2002306708A1 (en) In situ langerhans cell vaccine
IL164463A (en) Use of osteoprotegerin in the preparation of medicaments
TWI319400B (en) Piperazinylacylpiperidine derivatives, their preparation and their therapeutic application
AU2003224747A1 (en) Technetium-labeled rotenone derivatives, and methods of use thereof
DE60237654D1 (de) Komplexes Lithium-Mangan-Oxid, dessen Herstellung und Verwendung
AU2003296369A1 (en) Imminoamines and preparation thereof
AU2003224313A1 (en) Mycobacterial antigens and uses thereof
ZA200210316B (en) Composition and its therapeutic use.
AU2003259374A1 (en) Vaccine comprising il-13 and an adjuvant
PL371382A1 (en) Combinations of epinastine, belladonna and pseudoephedrine as new pharmaceutical formulations
AU2003255544A1 (en) Tumor specific oligosaccharide epitopes and use thereof
AU2003292751A1 (en) Hair care composition
AU2003237332A1 (en) Anti-relp fusion antibodies, compositions, methods and uses
GB2409796B (en) Composition comprising proteinaceous material, its preparation and use
PL375309A1 (en) Acyloxypyrrolidine derivatives, preparation and therapeutic use thereof
GB0317376D0 (en) Immunogenic protein and uses thereof
AU2002315931A1 (en) Heterodimeric conjugates of neomycin-oxazolidinone, their preparation and their use

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase